Variables | No active CMV infection (N = 26) No. (%) | Active CMV mono-infection (N = 39) No. (%) | Active CMV co-infection (N = 19) No. (%) | P |
---|---|---|---|---|
Sex | ||||
Male | 15 (57.7) | 23 (59) | 16 (84.2) | 0.119 |
Female | 11 (42.3) | 16 (41) | 3 (15.8) | Â |
Age (years) | ||||
  < 16 | 17 (65.4) | 22 (56.4) | 10 (52.6) | 0.655 |
  ≥ 16 | 9 (34.6) | 17 (43.6) | 9 (47.4) |  |
Type of Leukemia | ||||
 AML | 6 (23) | 21 (53.8) | 9 (47.4) | 0.044 |
 ALL | 20 (76.9) | 18 (46.2) | 10 (52.6) |  |
Status of disease | ||||
 Newly diagnosed | 1 (4) | 6 (15.4) | 2 (10.5) | 0.342 |
 Remission | 20 (76.9) | 24 (61.5) | 10 (52.6) |  |
 Refractory or relapse | 5 (19.1) | 9 (23) | 7 (36.8) |  |
Chemotherapy received | ||||
 Before chemotherapy | 1 (3.8) | 6 (15.4) | 2 (10.5) | 0.802 |
 Post-induction | 7 (26.9) | 10 (25.7) | 4 (21) |  |
 Post-remission | 8 (30.8) | 13 (33.3) | 7 (36.8) |  |
 Post-salvage chemotherapy | 10 (38.5) | 10 (25.6) | 6 (31.6) |  |
Clinical outcome | ||||
 Alive | 24 (92.3) | 34 (87.2) | 14 (73.7) | 0.198 |
 Dead | 2 (7.7) | 5 (12.8) | 5 (26.3) |  |
Fever | 16 (61.5) | 28 (71.8) | 12 (63.1) | 0.646 |
Severe neutropenia | 11 (42.3) | 24 (61.5) | 13 (68.4) | 0.163 |
Prolonged neutropenia | 8 (30.8) | 20 (51.3) | 10 (52.6) | 0.752 |
Severe lymphopenia | 11 (42.3) | 18 (46.2) | 16 (84.2) | 0.009 |
Anemia | 7 (26.9) | 15 (38.5) | 6 (31.6) | 0.507 |
Thrombocytopenia | 7 (26.9) | 16 (41) | 6 (31.6) | 0.364 |
Skin rash | 2 (7.7) | 6 (15.4) | 8 (42.1) | 0.011 |
Mucositis | 1 (3.8) | 2 (5.2) | 2 (10.5) | – |
Pneumonia | 2 (7.7) | 7 (17.9) | 8 (42.1) | 0.016 |
Gastroenteritis | – | 7 (17.9) | 3 (15.8) | 0.084 |
Hepatitis | 2 (7.7) | 5 (12.8) | 5 (26.3) | 0.198 |
Conjunctivitis | – | 2 (5.2) | – | – |
CNS disorders | 1 (3.8) | 2 (5.2) | 4 (21) | 0.073 |
Other infection | Â | Â | Â | Â |
BSI | 4 (15.4) | 4 (10.3) | 8 (42.1) | 0.013 |
IFI | 2 (7.7) | 5 (12.8) | 7 (36.8) | 0.024 |